NovoCure reports positive Phase 2 pancreatic cancer trial, 74% disease control vs. 48% standard

Filed March 26, 2026 · Period ending March 26, 2026 · ~1 min read

Key Changes

• high

  PANOVA-4 trial met primary endpoint: 74.4% disease control rate with TTFields plus immunotherapy and chemo versus 48% with chemo alone (p<0.001), a 26.4 percentage point improvement in metastatic pancreatic cancer patients.

  Item 7.01 Press Release verify on EDGAR →
• high

  Trial tested TTFields as first-line treatment for metastatic pancreatic ductal adenocarcinoma, a difficult-to-treat cancer, potentially opening a new indication beyond NovoCure's current approved uses.

  Item 7.01 Press Release verify on EDGAR →
• medium

  Results compare favorably to historical control from Phase 3 MPACT study (N=431 patients on standard chemotherapy), with statistical significance supporting potential efficacy of the combination approach.

  Item 7.01 Press Release verify on EDGAR →